Since 2011, Dendreon has changed chief executives twice and reduced its staff to about 700, about half the peak level. It still lost $22 million in the most recent quarter. The company’s stock was down about 70 percent, at about 30 cents a share ...
Deal Book · 3y
The stock is now higher by 1.18 at $29.32, with volume beginning to accelerate in the last few minutes. Dendreon Corp. is now challenging resistance at the highs of the year. The stock is trading at its highest level since mid-November.
RTTNews · 8y
Despite Tuesday's sharp decline, Dendreon's shares have gained 0.89% in the last five trading sessions and 11.60% in the last one month. Nonetheless, in the last three months, the stock has fallen by 0.22%. A free technical analysis on DNDN …
4-Traders · 4y
Shares in Dendreon Corp have gone through the roof after the US firm presented highly positive late-stage data on its investigational prostate cancer vaccine Provenge. The company says that its Phase III IMPACT study of Provenge (sipuleucel-T) in men with ...
Shares of Dendreon shed most of their value Monday before markets opened, sinking 67 cents to 27 cents. The stock had slipped below $1 earlier this fall and has tumbled most of this year after closing 2013 at $2.99.
CHICAGO — A small proportion of men with advanced prostate cancer for whom other treatments have failed may experience a significant and ongoing benefit with the programmed death ligand 1 (PD-L1) inhibitor pembrolizumab (Keytruda, Merck), say UK ...
Medscape · 13d
March 3 (Reuters) - Biotechnology company Dendreon Corp (NasdaqGS ... The Seattle-based company's stock was trading at $3.30 before the bell. (Reporting by Natalie Grover and Esha Dey in Bangalore; Editing by Sriraj Kalluvila)
"We think stock could trade up with the removal of this overhang." Shares of Seattle-based Dendreon increased 36 percent this year even after having fallen 29 percent since Provenge's approval April 29 because of reimbursement and supply concerns.
Dendreon's stock price took a hit, as investors tried to second-guess which way the winds were blowing at the agency. But as the previous panel had voted for approval with clinical data that fell short of statistical significance, it seemed unlikely that ...
Nature · 1y
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free. Here are highlights from Tuesday’s Analyst Blog: Is Dendreon Up for Sale? Dendreon Corp.’s ( DNDN- Free Report) share price jumped more than …